Figure 3. Kaplan-Meyer analysis for recurrence-free survival according to HER2 expression in node-negative patients (A), node-positive patients (B), patients with IDC (C) and patients with ILC and/or mixed IDC/ILC (D). HER2: Human epidermal growth factor receptor-2; FU: follow-up; IDC: infiltrative ductal carcinoma; ILC: infiltrative lobular carcinoma.
